Merck KGaA pitches in an extra $3M to support Opexa's PhIIb for MS

After gaining an option on Opexa's experimental drug for secondary progressive multiple sclerosis for only $5 million, Merck KGaA's Serono division has come up with an extra $3 million to support the biotech's ongoing Phase IIb study. The two companies struck the option deal back in 2013 on Tcelna (imilecleucel-T). It remains one of Merck KGaA's last investments in a scaled-down program for MS as the company also backs away from early-stage R&D in the field. Release

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.